Asia Pacific Metagenomics Market Size & Outlook, 2023-2030
Asia Pacific metagenomics market, 2018-2030 (US$M)
Related Markets
Asia Pacific metagenomics market highlights
- The Asia Pacific metagenomics market generated a revenue of USD 374.6 million in 2023.
- The market is expected to grow at a CAGR of 14% from 2024 to 2030.
- In terms of segment, kits & reagents was the largest revenue generating product in 2023.
- Sequencing & Data Analytics Services is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 374.6 million |
| Market revenue in 2030 | USD 938.3 million |
| Growth rate | 14% (CAGR from 2023 to 2030) |
| Largest segment | Kits & reagents |
| Fastest growing segment | Sequencing & Data Analytics Services |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Kits & Reagents, Sequencing & Data Analytics Services, Software |
| Key market players worldwide | Bio-Rad Laboratories Inc, Illumina Inc, PerkinElmer, Thermo Fisher Scientific Inc, Novogene, Promega, Qiagen NV, Takara Bio Inc, Oxford Nanopore Technologies PLC, Roche Holding AG |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.5% of the global metagenomics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 938.3 million by 2030.
Kits & reagents was the largest segment with a revenue share of 61.45% in 2023. Horizon Databook has segmented the Asia Pacific metagenomics market based on kits & reagents, sequencing & data analytics services, software covering the revenue growth of each sub-segment from 2018 to 2030.
Healthcare and clinical research service providers in Japan have been integrating Next-Generation Sequencing (NGS) technologies for the past couple of years. They are expected to account for a considerable share of Asia Pacific metagenomics revenue share.
Ongoing developments in HLA and prenatal NGS testing, coupled with international collaborations with U.S. & European companies, are expected to fuel the growth of Japan metagenomics market during the forecast period. Moreover, many hospitals in Japan have started using NGS-based mutational profile screening for patients with solid tumors to direct patients to relevant clinical trials.
Various cancer gene panels to be used in clinical practice have also been approved by the Ministry of Health, Labour and Welfare of Japan. However, a medical protocol for reporting and interpreting clinical variants must be developed. Using sequencing technology in this field, significant progress has been made in understanding the molecular causes of cancer.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Metagenomics Market Scope
Metagenomics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific metagenomics market size, by country, 2018-2030 (US$M)
Asia Pacific Metagenomics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
